These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36522630)

  • 1. Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040).
    Fukui T; Sasaki J; Igawa S; Kada A; Saito TI; Kogure Y; Okamoto H; Naoki K
    BMC Cancer; 2022 Dec; 22(1):1314. PubMed ID: 36522630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).
    Wakuda K; Yamaguchi H; Kenmotsu H; Fukuda M; Takeshita M; Suetsugu T; Kirita K; Ebi N; Hataji O; Miura S; Chibana K; Okamoto I; Yoshimura K; Nakagawa K; Yamamoto N; Sugio K
    BMC Cancer; 2020 May; 20(1):370. PubMed ID: 32357848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
    Asahina H; Tanaka K; Morita S; Maemondo M; Seike M; Okamoto I; Oizumi S; Kagamu H; Takahashi K; Kikuchi T; Isobe T; Sugio K; Kobayashi K
    Clin Lung Cancer; 2021 Mar; 22(2):147-151. PubMed ID: 33199228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study Design and Rationale for the PACE-LUNG Trial: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib First-Line Treatment.
    Acker F; Aguinarte L; Althoff F; Heinzen S; Rost M; Wild P; Reiser L; Mänz M; Meyer F; Stratmann J; Sebastian M
    Clin Lung Cancer; 2022 Nov; 23(7):e473-e477. PubMed ID: 36089483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
    Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N
    JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uncommon
    Okuma Y; Shimokawa M; Hashimoto K; Mizutani H; Wakui H; Murakami S; Atagi S; Minato K; Seike M; Ohe Y; Kubota K;
    Future Oncol; 2022 Feb; 18(5):523-531. PubMed ID: 35034503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
    Tsubata Y; Watanabe K; Saito R; Nakamura A; Yoshioka H; Morita M; Honda R; Kanaji N; Ohizumi S; Jingu D; Nakagawa T; Nakazawa K; Mouri A; Takeuchi S; Furuya N; Akazawa Y; Miura K; Ichihara E; Maemondo M; Morita S; Kobayashi K; Isobe T
    Int J Clin Oncol; 2022 Jan; 27(1):112-120. PubMed ID: 34643820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study).
    Hiranuma O; Uchino J; Yamada T; Chihara Y; Tamiya N; Kaneko Y; Yoshimura K; Takayama K
    Clin Lung Cancer; 2019 May; 20(3):e402-e406. PubMed ID: 30905617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of lazertinib for symptomatic or asymptomatic brain metastases in treatment-naive patients with advanced EGFR mutation-positive non-small cell lung cancer: Protocol of an open-label, single-arm phase II trial.
    Lee B; Ji W; Lee JC; Song SY; Shin YS; Cho YH; Park JE; Park H; Choi CM
    Thorac Cancer; 2023 Aug; 14(22):2233-2237. PubMed ID: 37365915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study.
    Igawa S; Fukui T; Kasajima M; Ono T; Ozawa T; Kakegawa M; Kusuhara S; Sato T; Nakahara Y; Hisashi M; Sasaki J; Naoki K
    Invest New Drugs; 2022 Apr; 40(2):430-437. PubMed ID: 34807331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
    Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T;
    Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world data on treatment outcomes in
    Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
    Akamatsu H; Katakami N; Okamoto I; Kato T; Kim YH; Imamura F; Shinkai M; Hodge RA; Uchida H; Hida T
    Cancer Sci; 2018 Jun; 109(6):1930-1938. PubMed ID: 29697876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
    Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
    Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial.
    Li A; Chen HJ; Yang JJ
    Clin Lung Cancer; 2023 Jan; 24(1):82-88. PubMed ID: 36333268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study).
    Okuma Y; Nomura S; Ninomiya K; Gyotoku H; Murakami S; Kogure Y; Harada D; Okishio K; Okamoto H; Goto Y
    Future Oncol; 2023 Jul; 19(22):1515-1521. PubMed ID: 37577772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.
    Chihara Y; Takeda T; Goto Y; Nakamura Y; Tsuchiya-Kawano Y; Nakao A; Onoi K; Hibino M; Fukuda M; Honda R; Yamada T; Taniguchi R; Sakamoto S; Date K; Nagashima S; Tanzawa S; Minato K; Nakatani K; Izumi M; Shimose T; Kishimoto J; Uchino J; Takayama K
    Oncologist; 2022 Nov; 27(11):903-e834. PubMed ID: 36181763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
    Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
    Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator).
    Tamiya A; Isa SI; Taniguchi Y; Nakagawa H; Atagi S; Ando M; Koh Y
    Clin Lung Cancer; 2021 May; 22(3):e336-e341. PubMed ID: 32641247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.